"Rising Concerns Over Weight Loss Drugs: Efficacy, Risks, and Shortages"
The Banner Poison Drug and Information Center in Arizona has reported a significant increase in calls related to popular weight-loss drugs, with the number of calls more than doubling from 40 in 2022 to 95 in 2023. The drugs in question, such as Ozempic and Wegovy, contain Semaglutide and are approved for type two diabetes treatment but are also used off-label for weight loss. Misuse, including self-administration of incorrect doses, has led to severe side effects like dehydration, nausea, and vomiting. Health professionals urge users to discuss potential adverse reactions with their doctors and to monitor symptoms closely.